

**Friday, 17 February**

Date & time	Speaker	Topic
08.30 - 08.40	Prof Nicolas Novitzky	Welcome address
Chairman: Prof M Patel (Session 1) 08.40 - 09.10	Prof Olle Ringden	Mesenchymal stem cells for treatment of graft-versus-host disease and tissue toxicity in hematopoietic stem cell transplantation.
09.10 – 10.00	Autologous stem cell transplantation is not indicated in systemic light chain amyloidosis.  Dr D Moodley  Dr J P Singh	Clinical Debate 1
<b>10.00 – 10.30</b>	<b>Tea</b>	
Chairman: Dr M du Toit (Session2) 10.30 - 11.20	Prof Olle Ringden	HSCT for ALL from HLA-identical siblings or matched unrelated donors. Does the outcome differ?
11.20 - 12.20	<ol style="list-style-type: none"> <li>1. Prof M Patel</li> <li>2. Dr J Thomson</li> <li>3. Dr D Reynders</li> <li>4. Prof N Novitzky (1)</li> </ol>	Proffered papers – Session 1
<b>12.20 - 13.15</b>	<b>Lunch</b>	
Chairwoman: Dr J Thomson (Session 3) 13.15 – 14.00	Prof Mohamad Mohty	Latest advances in stem cell mobilization.

<b>14.00 - 14.30</b>	<b>Tea</b>	
Chairman: Dr V Louw (Session 4)		
14.30 – 15.15	<p>Granulocytic growth factors are effective to shorten the period of neutropenia but should not be used following allogeneic stem cell transplantation.</p> <p>Yes: Dr C du Toit</p> <p>No to growth factors: Dr M du Toit</p>	Clinical Debate 2
15.15 - 16.05	Dr Paul Roux	<b>Ethics Talk:</b> 'Hammurabi, Moses, John Rawls and Ethics in the Transplant Unit'.
<b>16.30 - 18.30</b>	<b>AGM</b>	
<b>19.00</b>	<b>DINNER</b>	

**Saturday, 18 February**

Date & time	Speaker	Topic
<b>08.00-10.30</b>	<b>Mini symposium: Preventing Graft Failure in Allo Transplantation</b>	
Chairman: Prof N Novitzky (Session 1)		
08.00 - 08.30	Prof Nicolas Novitzky	Alemtuzumab and the CD52 antigen.
08.30 - 09.10	Prof Olle Ringden	Risk-factors for outcome and prevention of graft failure after allogeneic hematopoietic stem cell transplantation.
09.10 - 09.45	Prof Mohamad Mohty	ATG as a backbone for reduced intensity and toxicity conditioning.
09.45 – 10.00	Dr Karen Shires	Definition of Chimerism following Allogeneic Stem Cell Transplantation.
10.00 – 10.30	Round table discussion: Biological meaning of loss of Donor Chimerism.	
<b>10.30 - 11.00</b>	<b>Tea</b>	
Chairman: Dr SD Moodley (Session 2)		
11.00 – 11.45	A young 6 yr old female, Ph+ ALL in remission, we are able to give Gleevec but she also has a HLA matched sibling. Transplant or not?  Dr D Reynders  Prof A Davidson	Clinical Debate 3
<b>11.45 – 12.45</b>	<b>Lunch</b>	

<p>Chairwoman: Dr C du Toit (Session 3)</p> <p>12.45 – 13.45</p>	<ol style="list-style-type: none"> <li>1. Ms G Davison</li> <li>2. Prof E du Toit</li> <li>3. Dr D Brittain</li> <li>4. Prof N Novitzky (2)</li> </ol>	<p>Proffered papers – Session 2</p>
<p>13.45 - 14.30</p>	<p>Prof Mohamad Mohty</p>	<p>Treatment options for high risk and relapsed AML.</p>
<p><b>14.30 – 14.45</b></p>	<p><b>Closure</b></p>	
<p>15.00</p>	<p>Departure</p>	